Xarelto Lawsuit Filed Against Makers of Xarelto
A husband and wife from Ohio filed suit against the makers of the drug Xarelto, charging that it directly caused the woman to suffer significant health issues, including a potentially fatal bleeding episode and anemia.
In recent months, many of these product liability suits against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) were consolidated into a multidistrict litigation (MDL 2592), which will be tried in the Eastern District of Louisiana under Judge Eldon Fallon.
While it was initially heralded as a wonder drug, Xarelto has since accumulated more than 3,000 lawsuits against it, many with similar claims. The plaintiffs claim that they were placed at undue risk to suffer catastrophic bleeding events, some of which proved fatal, by taking the drug.
$150,000 in damages
The Ohio couple is seeking more than $150,000 in damages to defray the cost of existing medical expenses and the future care for her injuries. Originally, she was prescribed the new-generation anticoagulant because she suffers from a cardiac disorder known as atrial fibrillation. This can often place individuals at a heightened risk for stroke.
According to the claim, she began experiencing difficulties within two months of beginning the Xarelto regimen. A rupture in her intestinal blood vessels was continuing to bleed, due to the anti-clotting action of the drug. The suit claims that this contributed directly to anemia and other factors that have substantially impaired her ability to live a full life.
The FDA approved Xarelto for public use in 2011 as a new way to prevent blood clots.
Originally, its stated uses included treatment for those suffering from pulmonary embolism or deep vein thrombosis and patients recovering from hip or knee replacement surgeries. However, the approved uses soon expanded to include it as a preventative measure in the treatment of atrial fibrillation.
For more information, see Xarelto Bellwether Trials Set.